A pivotal Phase 3 trial of CK-101 in treatment-naive EGFR mutation-positive NSCLC patients
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2019
Price : $35 *
At a glance
- Drugs CK 101 (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Checkpoint Therapeutics
- 08 Aug 2019 According to a Checkpoint Therapeutics media release, the company plans to begin this trial in 2020.
- 17 Sep 2018 New trial record
- 06 Sep 2018 According to a Checkpoint Therapeutics media release, the trial is targeted to commence in 2019.